NRC Health Files Amended 2025 Annual Report: Key Details for Investors

Overview

NRC Health (NASDAQ: NRC), formerly known as National Research Corporation, has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. This amendment provides critical disclosures omitted from the original filing, primarily covering executive and director compensation, board composition, governance matters, and related shareholder information. The amendment was necessary because the company will not file its definitive proxy statement within 120 days of year-end.

Key Points Investors Should Note

• Purpose of the Amendment: The amendment includes information required by Items 10-14 of Part III of Form 10-K, such as details on directors, executive officers, governance, compensation, and principal accountant fees. No new financial statements or restated financials are included.
• Market Capitalization: As of June 30, 2025, the aggregate market value of NRC Health’s common stock held by non-affiliates was \$194.76 million. As of April 24, 2026, there were 22,536,696 shares of common stock outstanding.
• Board and Committee Structure: The company has a well-defined board structure:
  • Four board meetings in 2025; all directors attended at least 75% of meetings and committees served.
  • Standing committees include Audit, Compensation and Talent, Nominating, and Strategic Planning Committees, each with formal charters.
  • The Audit Committee, comprised entirely of independent directors, oversees financial reporting and cybersecurity risks, with John N. Nunnelly serving as the “audit committee financial expert.”
• Executive Compensation – Noteworthy Changes & Awards:
  • CEO Compensation: In 2025, new CEO Trent Green received a significant compensation package, including:
    • Cash Bonus: \$4,503,333
    • Equity Grant: 500,000 shares of NRC common stock, with multi-year vesting and transfer restrictions.
    • Additional Bonus (April 2026): \$1,860,000 to cover tax obligations after amending award terms to eliminate repurchase rights on equity grants.
  • CFO Compensation: Shane Harrison, new CFO as of late 2025, received:
    • Equity Grant: 172,000 restricted shares vesting over multiple years.
    • Cash Incentive: In line with company policy to offset tax obligations due to vesting restrictions.
  • Other Named Executive Officers: EVP Helen L. Hrdy and EVP & Chief Corporate Development Officer Mr. Monnich received bonuses of \$483,000 each, also to offset tax obligations for their equity grants.
  • Director Compensation: Standard director compensation consisted of cash payments and option awards:
    • Annual cash fees ranged from \$75,000–\$125,000 depending on committee roles.
    • Option awards valued at \$100,000–\$150,000 each year, vesting before the next annual meeting.
• Clawback and Trading Policies:
  • Clawback Policy: Covers current and former Section 16 officers, allowing recovery of incentive-based compensation in the event of financial restatements, misconduct, or breach of covenants.
  • Insider Trading Policy: Applies to all associates and prohibits hedging transactions; no officers or directors currently engage in hedging.
• Corporate Governance and Compliance:
  • All directors, officers, and 10% shareholders complied with Section 16(a) filing requirements, except for a few isolated late filings (none deemed material).
  • Company follows rigorous ethical guidelines under a public Code of Business Conduct and Ethics.
• Say-on-Pay: In May 2025, shareholders approved the executive compensation plan by approximately 99% of votes cast, strongly endorsing the company’s approach.
• Risk Assessment: The Compensation and Talent Committee found the company’s compensation policies do not encourage excessive risk-taking and are not likely to have a material adverse effect.

Potentially Price-Sensitive Information for Shareholders

• Large Executive Awards and Amendments: The significant equity and cash bonuses awarded to new CEO Trent Green and other top executives, especially the subsequent amendments to remove repurchase rights and the large cash bonuses to cover related tax obligations, may be seen as both an alignment with shareholder interests and a substantial cash outflow. These actions could affect investor sentiment regarding executive pay and the company’s cash position.
• Governance Transparency: The company’s detailed disclosures about governance, compensation, and compliance signal a strong commitment to transparency, which may be viewed positively by institutional investors.
• No Restatement of Financials: Importantly, this amendment does NOT correct or restate any financial statements, nor does it cite any material weaknesses in internal controls.
• Compensation Philosophy: The company’s compensation philosophy emphasizes competitive pay, alignment with shareholders, and avoidance of excessive perquisites or risky short-term incentives. This may reduce concerns about governance risk.

Conclusion

The amended 10-K/A filing from NRC Health provides investors with substantial new detail on executive compensation, governance, and compliance. The noteworthy size of the new CEO’s compensation, the major bonuses to cover tax burdens on equity awards, and the amendment of share restrictions to align with shareholder interests are all newsworthy and may influence investor perceptions and potentially the share price. Shareholders should review these disclosures carefully, as they highlight both the company’s commitment to attracting top executive talent and the financial costs associated with these actions.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please review the full SEC filings and consult your financial advisor before making any investment decisions related to NRC Health.

View NRC HEALTH Historical chart here